Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Sodium-Glucose Transporter 2 Inhibitors”

390 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 390 results

Early research (Phase 1)Looking for participantsNCT07053319
What this trial is testing

SGLT2i, Pioglitazone, and Ketone Production in T2D

Who this might be right for
Type 2 Diabetes
The University of Texas Health Science Center at San Antonio 64
Not applicableActive Not RecruitingNCT05944432
What this trial is testing

CGM Use in Adults With Type 2 Diabetes on Basal Insulin

Who this might be right for
Diabetes Mellitus, Type 2
Abbott Diabetes Care 470
Testing effectiveness (Phase 2)Not Yet RecruitingNCT03867487
What this trial is testing

SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease

Who this might be right for
Non-Alcoholic Fatty Liver DiseaseNAFLDPediatric NAFLD
Justin Ryder 40
Post-approval studies (Phase 4)Study completedNCT06026787
What this trial is testing

Clinical Value of Adding Dapagliflozin in Patients With Nephrotic Syndrome

Who this might be right for
Nephrotic SyndromeSodium-Glucose Transporter 2 Inhibitors
Ain Shams University 60
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07175051
What this trial is testing

Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin

Who this might be right for
Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)Albuminuria
University of Illinois at Chicago 20
Not applicableLooking for participantsNCT05897489
What this trial is testing

SGLT2 for Heart Failure in CHD Patients

Who this might be right for
Heart Failure
Centre Hospitalier Universitaire de Nice 100
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06072326
What this trial is testing

DApagliflozin SC0062 and Prevention of Renal Injury; a Randomized Evaluation

Who this might be right for
Type 1 Diabetes Mellitus With Diabetic Nephropathy
University Medical Center Groningen 36
Post-approval studies (Phase 4)Study completedNCT03030235
What this trial is testing

Dapagliflozin in PRESERVED Ejection Fraction Heart Failure

Who this might be right for
Chronic Heart Failure With Preserved Systolic Function
Saint Luke's Health System 324
Large-scale testing (Phase 3)Study completedNCT02874807
What this trial is testing

Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND Study

Who this might be right for
SIADH
University Hospital, Basel, Switzerland 88
Not applicableStudy completedNCT05764811
What this trial is testing

SGLT-2 Inhibitor Effects on Cardiac and Hepatic Metabolic Profiles for the Diabetes Patients Combined With Obesity

Who this might be right for
Fatty Liver Disease
National Cheng-Kung University Hospital 40
Post-approval studies (Phase 4)UnknownNCT03573102
What this trial is testing

Effect of Sodium Glucose co Transporter 2 Inhibitor ( SGLT2) on Proteinuria in Diabetic Patients

Who this might be right for
Diabetic Nephropathies
Nahla H Tohami 60
Not applicableUnknownNCT05934071
What this trial is testing

Effects of the Sodium-glucose Cotransporter 2 Inhibitors+Sacubitril/Valsartan Therapy in Patients With HFrEF.

Who this might be right for
Heart FailureVentricular RemodelingVentricular Dysfunction
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 160
Post-approval studies (Phase 4)UnknownNCT05152940
What this trial is testing

ERTU-SODIUM: Study on the Effects of Ertugliflozin on Sodium Storage, Interstitial Volume, and Plasma Volume in HFrEF

Who this might be right for
Heart Failure With Reduced Ejection FractionCongestion
Icahn School of Medicine at Mount Sinai 28
Post-approval studies (Phase 4)Not Yet RecruitingNCT07323524
What this trial is testing

Dapagliflozin in Active Lupus Nephritis

Who this might be right for
Lupus Nephritis (LN)
Brigham and Women's Hospital 33
Early research (Phase 1)Not Yet RecruitingNCT07172971
What this trial is testing

Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy

Who this might be right for
Duchenne Muscular Dystrophy (DMD)
Larry W. Markham 10
Not applicableStudy completedNCT03817463
What this trial is testing

Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes

Who this might be right for
Diabetes Mellitus, Type 2
Boehringer Ingelheim 327,624
Not applicableStudy completedNCT02966626
What this trial is testing

A Real World Experience of Dapagliflozin in Type 2 Diabetes

Who this might be right for
Type2 Diabetes
University of Malaya 223
Not applicableLooking for participantsNCT06090591
What this trial is testing

Cardiology Research Dubrava Prospective Registry

Who this might be right for
Heart FailureArrhythmias, CardiacAtrial Fibrillation+1 more
University Hospital Dubrava 3,000
Very early researchEnded earlyNCT06124924
What this trial is testing

SGLT2 Inhibitors After Acute Kidney Injury With Indications Pilot

Who this might be right for
Acute Kidney Injury
University of Minnesota 1
Not applicableLooking for participantsNCT07491042
What this trial is testing

Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients.

Who this might be right for
End Stage Chronic Renal Failure
Oman Ministry of Health 38
Load More Results